Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 2113 to 2162 of 3228 in total 
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2113\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ran-binding protein 2-like 1 isoform 2; sperm membrane protein bs-63; ran-binding protein 2-like 1. [source:refseq;acc:nm\_032260]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
219.055\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
217.533\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.007\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2114\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LIPF\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
triacylglycerol lipase, gastric precursor (ec 3.1.1.3) (gastric lipase) (gl). [source:swissprot;acc:p07098]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
214.632\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
213.14\vspace{3pt}}}&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2115\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LIPM\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ba304i5.1 (novel lipase) (fragment). [source:sptrembl;acc:q96lg2]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2116\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LIPA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
lysosomal acid lipase/cholesteryl ester hydrolase precursor (ec 3.1.1.13) (lal) (acid cholesteryl ester hydrolase) (sterol esterase) (lipase a) (cholesteryl esterase). [source:swissprot;acc:p38571]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2117\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SARS2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
seryl-trna synthetase, mitochondrial precursor (ec 6.1.1.11) (serine--trna ligase) (serrsmt). [source:swissprot;acc:q9np81]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2118\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SARS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
seryl-trna synthetase (ec 6.1.1.11) (serine--trna ligase) (serrs). [source:swissprot;acc:p49591]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2119\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KCMF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
potassium channel modulatory factor 1; potassium channel modulatory factor; differentially expressed in branching tubulogenesis 91; zinc finger, zz domain containing 1. [source:refseq;acc:nm\_020122]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
221.248\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
222.788\vspace{3pt}}}&\multirow{21}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00696\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2120\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC23A1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
solute carrier family 23, member 1 (sodium-dependent vitamin c transporter 1) (hsvct1) (na(+)/l-ascorbic acid transporter 1) (yolk sac permease-like molecule 3). [source:swissprot;acc:q9uhi7]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2121\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HNRPA3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
heterogeneous nuclear ribonucleoprotein a3 (hnrnp a3) (d10s102). [source:swissprot;acc:p51991]\vspace{3pt}}&&&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2122\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LGALS9\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
galectin-9 (hom-hd-21) (ecalectin). [source:swissprot;acc:o00182]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.473\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.911\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2123\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARF4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adp-ribosylation factor 4. [source:swissprot;acc:p18085]\vspace{3pt}}&\multirow{8}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
221.248\vspace{3pt}}}&\multirow{8}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
222.788\vspace{3pt}}}&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2124\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AKTIP\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
fused toes homolog; likely ortholog of mouse fused toes. [source:refseq;acc:nm\_022476]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2125\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHC1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
shc transforming protein. [source:swissprot;acc:p29353]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2126\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZNF289\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
zinc finger protein 289, id1 regulated; likely ortholog of mouse zfp289. [source:refseq;acc:nm\_032389]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2127\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHC3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
neuronal shc. [source:refseq;acc:nm\_016848]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2128\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARF1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adp-ribosylation factor 1. [source:swissprot;acc:p32889]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2129\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HNRNPA1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
heterogeneous nuclear ribonucleoprotein a1 (helix-destabilizing protein) (single-strand binding protein) (hnrnp core protein a1). [source:swissprot;acc:p09651]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2130\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARF3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adp-ribosylation factor 3. [source:swissprot;acc:p16587]\vspace{3pt}}&&&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2131\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GCH1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
gtp cyclohydrolase i (ec 3.5.4.16) (gtp-ch-i). [source:swissprot;acc:p30793]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
226.277\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
227.851\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2132\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SHC2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein sck (fragment). [source:swissprot;acc:p98077]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.248\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
222.788\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2133\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NR4A1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
orphan nuclear receptor hmr (early response protein nak1) (tr3 orphan receptor). [source:swissprot;acc:p22736]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.74\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
206.305\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2134\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HNRNPA2B1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
heterogeneous nuclear ribonucleoproteins a2/b1 (hnrnp a2 / hnrnp b1). [source:swissprot;acc:p22626]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.248\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
222.788\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2135\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NR4A3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nuclear hormone receptor nor-1 (neuron-derived orphan receptor 1) (mitogen induced nuclear orphan receptor). [source:swissprot;acc:q92570]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.743\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
206.308\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2136\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
OCIAD1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ovarian carcinoma immunoreactive antigen. [source:refseq;acc:nm\_017830]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
221.248\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
222.788\vspace{3pt}}}&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2137\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARFGAP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adp-ribosylation factor gtpase-activating protein 3 (arf gap 3). [source:swissprot;acc:q9np61]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2138\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SLC23A2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
solute carrier family 23, member 2 (sodium-dependent vitamin c transporter 2) (hsvct2) (na(+)/l-ascorbic acid transporter 2) (yolk sac permease-like molecule 2) (nucleobase transporter-like 1 protein). [source:swissprot;acc:q9ugh3]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2139\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP2K7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 7 (ec 2.7.1.-) (map kinase kinase 7) (mapkk 7) (mapk/erk kinase 7) (jnk activating kinase 2) (c-jun n-terminal kinase kinase 2) (jnk kinase 2) (jnkk 2). [source:swissprot;acc:o14733]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2140\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CSTF2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cleavage stimulation factor, 64 kda subunit (cstf 64 kda subunit) (cf-1 64 kda subunit). [source:swissprot;acc:p33240]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
161.547\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
162.665\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00692\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2141\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NR4A2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
orphan nuclear receptor nurr1 (immediate-early response protein not) (transcriptionally inducible nuclear receptor). [source:swissprot;acc:p43354]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.765\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
206.343\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00689\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2142\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EPB41\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein 4.1 (band 4.1) (p4.1) (epb4.1) (4.1r). [source:swissprot;acc:p11171]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.443\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.864\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00688\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2143\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SPTBN5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
spectrin beta chain, brain 4 (spectrin, non-erythroid beta chain 4) (beta-v spectrin) (bspecv). [source:swissprot;acc:q9nrc6]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.442\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.862\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2144\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EPB41L1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
band 4.1-like protein 1 (neuronal protein 4.1) (4.1n). [source:swissprot;acc:q9h4g0]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.443\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.864\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2145\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EPB41L3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
band 4.1-like protein 3 (4.1b) (differentially expressed in adenocarcinoma of the lung protein 1) (dal-1). [source:swissprot;acc:q9y2j2]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.442\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.862\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2146\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EPB41L2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
band 4.1-like protein 2 (generally expressed protein 4.1) (4.1g). [source:swissprot;acc:o43491]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.443\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.864\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2147\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SDF4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
45 kda calcium-binding protein precursor (cab45) (stromal cell-derived factor 4) (sdf-4). [source:swissprot;acc:q9brk5]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.442\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.862\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2148\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ba271b5.1 (similar to ribosomal protein s7). [source:sptrembl;acc:q9h1s9]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
217.871\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
219.366\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00686\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2149\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RPS7\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
40s ribosomal protein s7 (s8). [source:swissprot;acc:p23821]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2150\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSMD14\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
26s proteasome-associated pad1 homolog. [source:refseq;acc:nm\_005805]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2151\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APOB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
apolipoprotein b-100 precursor (apo b-100) [contains: apolipoprotein b-48 (apo b-48)]. [source:swissprot;acc:p04114]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2152\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAMP2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vesicle-associated membrane protein 2 (vamp-2) (synaptobrevin 2). [source:swissprot;acc:p19065]\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
200.063\vspace{3pt}}}&\multirow{6}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
198.71\vspace{3pt}}}&\multirow{6}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00681\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2153\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAMP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vesicle-associated membrane protein 1 (vamp-1) (synaptobrevin 1). [source:swissprot;acc:p23763]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2154\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAMP4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vesicule-associated membrane protein 4 (vamp-4). [source:swissprot;acc:o75379]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2155\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CDIPT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cdp-diacylglycerol--inositol 3-phosphatidyltransferase (ec 2.7.8.11) (phosphatidylinositol synthase) (ptdins synthase) (pi synthase). [source:swissprot;acc:o14735]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2156\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARFGAP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adp-ribosylation factor gtpase activating protein 1 (adp-ribosylation factor 1 gtpase activating protein) (arf1 gap) (arf1-directed gtpase- activating protein) (gap protein). [source:swissprot;acc:q8n6t3]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2157\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VAMP3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
vesicle-associated membrane protein 3 (vamp-3) (synaptobrevin 3) (cellubrevin) (ceb). [source:swissprot;acc:q15836]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2158\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LGALS4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
galectin-4 (lactose-binding lectin 4) (l-36 lactose binding protein) (l36lbp) (antigen ny-co-27). [source:swissprot;acc:p56470]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
206.401\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
207.796\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00676\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2159\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAPK3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mitogen-activated protein kinase 3 (ec 2.7.1.37) (extracellular signal-regulated kinase 1) (erk-1) (insulin-stimulated map2 kinase) (map kinase 1) (mapk 1) (p44-erk1) (ert2) (p44-mapk) (microtubule- associated protein-2 kinase). [source:swissprot;acc:p27361]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.921\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
214.474\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00675\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2160\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RPS6KA3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ribosomal protein s6 kinase alpha 3 (ec 2.7.1.37) (s6k-alpha 3) (90 kda ribosomal protein s6 kinase 3) (p90-rsk 3) (ribosomal s6 kinase 2) (rsk-2) (pp90rsk2) (insulin-stimulated protein kinase 1) (ispk-1). [source:swissprot;acc:p51812]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
215.925\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
214.481\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00673\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2161\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CAMK2G\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
calcium/calmodulin-dependent protein kinase type ii gamma chain (ec 2.7.1.123) (cam-kinase ii gamma chain) (cam kinase ii gamma subunit) (camk-ii gamma subunit) (fragment). [source:swissprot;acc:q13555]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2162\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CAMK2D\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
calcium/calmodulin-dependent protein kinase type ii delta chain (ec 2.7.1.123) (cam-kinase ii delta chain) (cam kinase ii delta subunit) (camk-ii delta subunit). [source:swissprot;acc:q13557]\vspace{3pt}}&&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/